Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
about
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Immune reconstitution in chronic lymphocytic leukemiaA phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K AxisLenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaA prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.The role of B7 family molecules in hematologic malignancyBiology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.Lenalidomide alone and in combination for chronic lymphocytic leukemia.Lenalidomide in lymphomas and chronic lymphocytic leukemia.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drugTrial Watch: Lenalidomide-based immunochemotherapy.Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia.Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.Cytokine release syndrome.Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia
P2860
Q26770391-BBD2F5D0-9F9B-4917-85C3-10B91FB65C23Q26865561-03465C34-7710-478E-96FC-C8EC903ACE45Q33391895-8DC12611-54C9-4B3E-932C-1570D01C0B30Q33817800-55FD31DF-EFF0-4FFF-B67F-9D6841F7A760Q34009041-4C62AC8A-3E3B-4CA3-A2C6-A760762A78B6Q34137016-5578224B-42B7-4BFD-9C30-6428F4BFCB0CQ34278096-507A74D4-6870-4AD1-9786-931BC1C8DED1Q34625543-3686C64B-A998-4F29-96CB-3888733EE50CQ34923824-A46B20F1-A172-45A6-9C7A-A0D39389CA97Q35033519-AC5FD067-250A-4B07-BE79-BAA5080C1D88Q35608564-75C9EEE2-5996-49D3-BB1D-E181C53FBE26Q35915614-C2BDDF58-39D7-4231-8159-DBE01638DB9BQ36003724-392BE1E0-55B2-4647-A9C7-008C55A957ACQ36149549-13AE283F-EC9D-4898-948B-3247358F862FQ36584814-FFC39D95-82F0-494B-829D-9F7DEFE728B3Q36862781-8422A4F8-EB06-44B3-8BFC-3B0808435175Q36920412-23EA5E67-4EA2-4763-8B68-1C152BC53A31Q36929831-7AC9A3FE-42AC-4025-840B-23050B0C17A8Q37958036-3177A57B-9F84-4D12-BF3D-33B501D924ECQ38068736-5E5B20DF-FB4D-4E86-8D26-0F0EF5FB86ADQ38077277-2CD58253-1EE1-40EE-9DF6-B599DDD79435Q38550810-EBEFC276-020B-4F97-8471-C6CC5FA014BBQ40778187-58964CFA-0C8C-4DBA-84E7-B0AABE9491B3Q42547378-2D390996-BF20-49BE-8BD8-F9028E821AF2Q42737828-E72261AB-9D88-4484-8E38-F332539FBD02Q42972724-BA525F35-D764-44D3-9D89-0D6BC749B42DQ43596419-0D04166F-3C70-4CE7-A71C-9EC9D16F9C3AQ50684564-83817ED4-96B4-405E-A2DE-08C8D1188822Q50864223-13E34D68-7936-49C0-A341-0C907B95689CQ51051144-EEB7F580-B5C2-4AD8-A6E7-579CC07F6584Q53740834-7199B4ED-F381-4929-AEF4-81E6485656B1Q55438228-85750353-C968-489C-AE5E-6EB038A02D50Q57807709-FE1CDE6D-86A7-4B59-B224-63C209F6599A
P2860
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lenalidomide-induced upregulat ...... chronic lymphocytic leukemia.
@en
Lenalidomide-induced upregulat ...... chronic lymphocytic leukemia.
@nl
type
label
Lenalidomide-induced upregulat ...... chronic lymphocytic leukemia.
@en
Lenalidomide-induced upregulat ...... chronic lymphocytic leukemia.
@nl
prefLabel
Lenalidomide-induced upregulat ...... chronic lymphocytic leukemia.
@en
Lenalidomide-induced upregulat ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P1433
P1476
Lenalidomide-induced upregulat ...... chronic lymphocytic leukemia.
@en
P2093
Adrian Wiestner
Berengere Vire
Carol Boss
Federica Gibellini
J Philip McCoy
Janet Valdez
Keyvan Keyvanfar
Leigh Samsel
Ndegwa Njuguna
P2860
P304
P356
10.3324/HAEMATOL.2009.005835
P577
2009-09-01T00:00:00Z